# SPARK-ALL: Calaspargase Pegol in Adults With ALL

> **NCT04817761** · PHASE2,PHASE3 · TERMINATED · sponsor: **Institut de Recherches Internationales Servier** · enrollment: 42 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Calaspargase pegol (S95015)

## Key facts

- **NCT ID:** NCT04817761
- **Lead sponsor:** Institut de Recherches Internationales Servier
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-07-07
- **Primary completion:** 2025-03-21
- **Final completion:** 2025-03-21
- **Target enrollment:** 42 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2026-02-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04817761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04817761, "SPARK-ALL: Calaspargase Pegol in Adults With ALL". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04817761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*